Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Locally Advanced or Metastatic Cancer in Response After 6 Months of Standard IO

NCT05078047 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT05078047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05078047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Locally Advanced or Metastatic Cancer in Response After 6 Months of Standard IO
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 8, 2022
Completion date
May 7, 2029
Enrollment
646 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

basal cell carcinoma, cervical cancer, colorectal carcinoma with microsatellite instability, endometrial carcinoma, esophageal squamous cell carcinoma, gastric/gastro-esophageal junction/esophageal adenocarcinoma, head and neck cancer, hepatocellular carcinoma, lung cancer metastatic, melanoma, merkel cell carcinoma, renal cell carcinoma, squamous skin carcinoma, triple negative breast cancer, urothelial carcinoma